Last reviewed · How we verify
YD0293
At a glance
| Generic name | YD0293 |
|---|---|
| Sponsor | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
- Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YD0293 CI brief — competitive landscape report
- YD0293 updates RSS · CI watch RSS
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. portfolio CI